🎉 M&A multiples are live!
Check it out!

Imugene Valuation Multiples

Discover revenue and EBITDA valuation multiples for Imugene and similar public comparables like AstraZeneca India, European Medical, and GSK India.

Imugene Overview

About Imugene

Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.


Founded

1986

HQ

Australia
Employees

3

Website

imugene.com

Financials

LTM Revenue $1.6M

LTM EBITDA -$82.6M

EV

$156M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Imugene Financials

Imugene has a last 12-month revenue of $1.6M and a last 12-month EBITDA of -$82.6M.

In the most recent fiscal year, Imugene achieved revenue of n/a and an EBITDA of -$90.1M.

Imugene expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Imugene valuation multiples based on analyst estimates

Imugene P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$32.3M -$90.1M XXX XXX XXX
EBITDA Margin NaN% NaN% XXX XXX XXX
Net Profit -$23.9M -$24.8M XXX XXX XXX
Net Margin NaN% NaN% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Imugene Stock Performance

As of March 17, 2025, Imugene's stock price is AUD 0 (or $0).

Imugene has current market cap of AUD 268M (or $169M), and EV of AUD 247M (or $156M).

See Imugene trading valuation data

Imugene Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$156M $169M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Imugene Valuation Multiples

As of March 17, 2025, Imugene has market cap of $169M and EV of $156M.

Imugene's trades at 98.9x LTM EV/Revenue multiple, and -1.9x LTM EBITDA.

Analysts estimate Imugene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Imugene and 10K+ public comps

Imugene Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $156M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E -2.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Imugene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Imugene Valuation Multiples

Imugene's NTM/LTM revenue growth is -100%

Imugene's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $30.7M for the same period.

Over next 12 months, Imugene's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Imugene's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Imugene and other 10K+ public comps

Imugene Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 179% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $30.7M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Imugene Public Comps

See public comps and valuation multiples for Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
CSL XXX XXX XXX XXX XXX XXX
Prescient Therapeutics XXX XXX XXX XXX XXX XXX
GSK India XXX XXX XXX XXX XXX XXX
AstraZeneca India XXX XXX XXX XXX XXX XXX
European Medical XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Imugene M&A and Investment Activity

Imugene acquired  XXX companies to date.

Last acquisition by Imugene was  XXXXXXXX, XXXXX XXXXX XXXXXX . Imugene acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Imugene

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Imugene

When was Imugene founded? Imugene was founded in 1986.
Where is Imugene headquartered? Imugene is headquartered in Australia.
How many employees does Imugene have? As of today, Imugene has 3 employees.
Who is the CEO of Imugene? Imugene's CEO is Ms. Leslie Chong.
Is Imugene publicy listed? Yes, Imugene is a public company listed on ASX.
What is the stock symbol of Imugene? Imugene trades under IMU ticker.
When did Imugene go public? Imugene went public in 1993.
Who are competitors of Imugene? Similar companies to Imugene include e.g. CSL, Prescient Therapeutics, GSK India, AstraZeneca India.
What is the current market cap of Imugene? Imugene's current market cap is $169M
What is the current revenue of Imugene? Imugene's last 12-month revenue is $1.6M.
What is the current EBITDA of Imugene? Imugene's last 12-month EBITDA is -$82.6M.
What is the current EV/Revenue multiple of Imugene? Current revenue multiple of Imugene is 98.9x.
What is the current EV/EBITDA multiple of Imugene? Current EBITDA multiple of Imugene is -1.9x.
Is Imugene profitable? Yes, Imugene is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.